U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT06931652) titled 'Study of Epcoritamab in Relapsed and Refractory Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab' on April 07.
Brief Summary: The purpose of this phase 2 study is to evaluate the efficacy and safety of epcoritamab in subjects with relapsed or refractory primary diffuse large B-cell lymphoma of the Central Nervous System treated with rituximab and lenalidomide.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Primary CNS Lymphoma (PCNSL)
Intervention:
DRUG: Epcoritamab
Epcoritamab Investigational Medicinal Product (IMP): Epcoritamab will be used during induction phase ...